Web Results


Jun 19, 2003 ... Case opinion for US 7th Circuit COOK INC v. BOSTON SCIENTIFIC CORPORATION. Read the Court's full decision on FindLaw.


Feb 6, 2018 ... Affirming the judgments in four consolidated cases where plaintiffs were awarded four million dollars each in a suit relating to transvaginal mesh devices, rejecting arguments that the consolidation resulted in prejudice, that there was insufficient evidence, and averring that one of the jury instructions was in ...


Jun 5, 2003 ... Case opinion for IL Supreme Court BRANDT v. BOSTON SCIENTIFIC CORPORATION. Read the Court's full decision on FindLaw.


Nov 10, 2015 ... Microspheres are small, spherical particles used by interventional radiologists to slow or stop the blood supply to a growth or tumor. ... CeloNova BioSciences, Inc. , headquartered in San Antonio, Texas, is a global medical device company that develops, manufactures and markets a family of interventional ...


cost comparison between flexible reusable fiberoptic ureteroscopes (URF-P6™) and LithoVue. Patients and Methods: For this prospective, single-center micro- costing study, all consecutive ureteroscopies performed during 1 week each in July and August 2016 utilized either URF-P6 or LithoVue ureteroscopes respectively.


Feb 27, 2013 ... Here, we developed a medaka fish (Oryzias latipes) model that is deficient in Pink1 and Parkin. We found that despite the lack of a conspicuous phenotype in single mutants for Pink1 or Parkin, medaka that are deficient in both genes developed phenotypes similar to that of human PD: late-onset locomotor ...


Feb 14, 2008 ... Pink1 Parkinson mutations, the Cdc37/Hsp90 chaperones and Parkin all influence the maturation or subcellular distribution of Pink1 ... PD-causing Pink1 mutations decrease whereas Parkin expression increases the Pink1 66/55 kDa protein ratio, biochemically linking Pink1 and Parkin and highlighting the ...


Mar 9, 2017 ... Here we show that mutations that we designed to activate Parkin by releasing the Repressor Element of Parkin (REP) domain, or by disrupting the ...... UbcH7 (10 μg) was charged with N-terminal fluorescein-labelled Ub (10 μg FluoUb) using 0.02 μg His6-E1 (Boston Biochem Inc.), 0.5 mM ATP and 10 mM ...


To investigate whether TFEB is activated during mitophagy, we treated HeLa cells stably expressing YFP-Parkin for up to 10 h with both the ATP synthase inhibitor oligomycin and the complex III inhibitor antimycin A (oligomycin/ antimycin A [O/A]; Fig. 1, A and B) or valinomycin (Fig. S1, A and B) to induce mitophagy.